Decreased neurofilament light chain levels in estriol-treated multiple sclerosis.
Rhonda R VoskuhlJens KuhlePrabha SiddarthNoriko ItohKevin PatelAllan MacKenzie-GrahamPublished in: Annals of clinical and translational neurology (2022)
Estrogens have neuroprotective actions depending on estrogen type, dose, and timing in both preclinical models and in women during health and disease. Serum neurofilament light chain is a putative biomarker of neurodegeneration in multiple sclerosis, aging, and other neurodegenerative diseases. Here, oral treatment with an estrogen unique to pregnancy (estriol) using an 8 mg dose to induce a mid-pregnancy blood estriol level reduced serum neurofilament light chain in nonpregnant MS women at mean age of 37 years. This is consistent with estriol-mediated protection from neuro-axonal injury and supports the use of serum neurofilament light chain as a biomarker in MS.
Keyphrases
- multiple sclerosis
- cerebrospinal fluid
- pregnancy outcomes
- polycystic ovary syndrome
- mass spectrometry
- white matter
- healthcare
- public health
- preterm birth
- ms ms
- pregnant women
- estrogen receptor
- mental health
- type diabetes
- mesenchymal stem cells
- metabolic syndrome
- insulin resistance
- skeletal muscle
- cerebral ischemia
- breast cancer risk
- replacement therapy
- social media